ZA200701158B - Combination therapy with radiolabeled anti-CD20 antibody in the treatment of B-cell lymphoma - Google Patents

Combination therapy with radiolabeled anti-CD20 antibody in the treatment of B-cell lymphoma

Info

Publication number
ZA200701158B
ZA200701158B ZA200701158A ZA200701158A ZA200701158B ZA 200701158 B ZA200701158 B ZA 200701158B ZA 200701158 A ZA200701158 A ZA 200701158A ZA 200701158 A ZA200701158 A ZA 200701158A ZA 200701158 B ZA200701158 B ZA 200701158B
Authority
ZA
South Africa
Prior art keywords
antibody
treatment
combination therapy
cell lymphoma
radiolabeled anti
Prior art date
Application number
ZA200701158A
Other languages
English (en)
Inventor
Krause Werne
Kuhlmann Jens
Kalmus Joachim
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200701158(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200701158B publication Critical patent/ZA200701158B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
ZA200701158A 2004-07-09 2007-02-08 Combination therapy with radiolabeled anti-CD20 antibody in the treatment of B-cell lymphoma ZA200701158B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58641404P 2004-07-09 2004-07-09

Publications (1)

Publication Number Publication Date
ZA200701158B true ZA200701158B (en) 2008-09-25

Family

ID=34972426

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701158A ZA200701158B (en) 2004-07-09 2007-02-08 Combination therapy with radiolabeled anti-CD20 antibody in the treatment of B-cell lymphoma

Country Status (13)

Country Link
US (2) US20060029543A1 (es)
EP (1) EP1765399A1 (es)
JP (2) JP2008505148A (es)
KR (1) KR101250127B1 (es)
AU (1) AU2005261923B2 (es)
BR (1) BRPI0513007A (es)
CA (1) CA2568526C (es)
IL (1) IL179636A (es)
MX (1) MX2007000327A (es)
NO (1) NO344366B1 (es)
RU (1) RU2394596C2 (es)
WO (1) WO2006005477A1 (es)
ZA (1) ZA200701158B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8061104B2 (en) 2005-05-20 2011-11-22 Valinge Innovation Ab Mechanical locking system for floor panels
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
US11055552B2 (en) * 2016-01-12 2021-07-06 Disney Enterprises, Inc. Systems and methods for detecting light signatures and performing actions in response thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3095175B2 (ja) * 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
NZ573838A (en) * 1998-08-11 2011-01-28 Biogen Idec Inc Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
ES2524141T3 (es) * 1999-04-01 2014-12-04 Talon Therapeutics, Inc. Composiciones para tratar el cáncer
JP2004500412A (ja) * 2000-03-31 2004-01-08 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗ｃｄ２０の併用
KR101033196B1 (ko) * 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
AU2003295649A1 (en) 2002-11-22 2004-06-18 Nuvelo,Inc. Methods of therapy and diagnosis

Also Published As

Publication number Publication date
JP6034314B2 (ja) 2016-11-30
MX2007000327A (es) 2007-03-12
CA2568526A1 (en) 2006-01-19
RU2007104839A (ru) 2008-08-20
WO2006005477A1 (en) 2006-01-19
US20060029543A1 (en) 2006-02-09
IL179636A0 (en) 2007-05-15
US20190112383A1 (en) 2019-04-18
KR101250127B1 (ko) 2013-04-02
BRPI0513007A (pt) 2008-04-22
NO344366B1 (no) 2019-11-18
JP2008505148A (ja) 2008-02-21
AU2005261923A1 (en) 2006-01-19
EP1765399A1 (en) 2007-03-28
IL179636A (en) 2013-09-30
RU2394596C2 (ru) 2010-07-20
NO20070763L (no) 2007-02-08
AU2005261923B2 (en) 2010-11-18
CA2568526C (en) 2015-11-03
JP2014080429A (ja) 2014-05-08
KR20070042527A (ko) 2007-04-23

Similar Documents

Publication Publication Date Title
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
PT3296407T (pt) Mutações do gene pik3ca em cancros humanos
IL172316A0 (en) Novel compounds and their use in therapy
ZA201001442B (en) Combination therapy with type i and type ii anti-cd20 antibodies
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
ZA200701193B (en) The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
GB0523576D0 (en) Drug composition and its use in therapy
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
IL177845A0 (en) Combination therapy with glatiramer acetate and riluzole
ZA200701158B (en) Combination therapy with radiolabeled anti-CD20 antibody in the treatment of B-cell lymphoma
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0428170D0 (en) Mono and Combination Therapy
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
HK1097495A1 (en) Can body and can
SG110107A1 (en) Compound and use in treatment
SI1639013T1 (sl) Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji
EP1666046A4 (en) USE OF N-ACETYL-D-AMINOGLYCOSAMINE FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CANCER AND METASTASES
EP1804795A4 (en) ENANTIOMERIC COMPOSITIONS OF CICLETANINE, ALONE OR COMBINED WITH OTHER AGENTS, USED FOR THERAPEUTIC PURPOSES
GB0424871D0 (en) Antibodies and their use in therapy
GB0416876D0 (en) Compound and use in treatment